This article is part of the HBOT Radar series, where we summarize the latest published hyperbaric oxygen therapy research.
Fresh Science, Clearly Explained — Brought to you by Brain Spa Hyperbaric
Disclaimer: This article is intended for educational and informational purposes only. It summarizes published medical research conducted in clinical settings and does not evaluate Brain Spa Hyperbaric products. The hyperbaric chambers offered on this website are non-medical wellness devices and are not intended to diagnose, treat, cure, or prevent any disease. Do not make medical decisions based on this article — consult a qualified healthcare professional.
📌 Your Jaw Bone Won't Heal. Could Pressurized Oxygen Help?
🔍 Why this topic matters
Here's a scenario most people never think about until it's their problem: you've had radiation treatment for head or neck cancer. The cancer's gone. But months or years later, you need a tooth pulled — and the wound won't heal. The bone underneath starts dying. It's called osteoradionecrosis (ORN), and it happens because radiation doesn't just kill cancer cells. It permanently damages the blood vessels in the surrounding tissue, leaving the bone chronically starved of oxygen.
Or maybe you've been taking bisphosphonates — medications prescribed for osteoporosis or cancer-related bone loss. They strengthen your bones everywhere except, paradoxically, your jaw. A routine dental procedure can trigger medication-related osteonecrosis of the jaw (MRONJ): exposed, dying bone that resists treatment and can persist for months or years.
These aren't rare curiosities. ORN affects up to 15% of head and neck cancer survivors. MRONJ, while less common, is a growing concern as more patients take bone-modifying medications long-term. And in both cases, the fundamental problem is the same: the tissue is so damaged and oxygen-deprived that it can't do what healthy tissue does after surgery — heal.
Which raises an obvious question: what if you could flood that oxygen-starved tissue with oxygen under pressure?
A team from Poznan University of Medical Sciences in Poland set out to answer this by reviewing 123 published studies spanning 25 years of research on HBOT in dental and oral surgery.
🔬 What the researchers reviewed
This is a narrative review — meaning the researchers systematically searched PubMed, Web of Science, Cochrane Library, and Scopus for English-language publications from 2000 to September 2025 that addressed HBOT in oral and maxillofacial surgery. They weren't testing HBOT themselves; they were gathering and evaluating everything that's been published.
Out of 899 unique records, 123 publications made the final cut — including randomized controlled trials, observational studies, case reports, preclinical animal research, and systematic reviews. They organized findings across five clinical areas: osteoradionecrosis (ORN), medication-related jaw necrosis (MRONJ), dental implants in compromised patients, post-extraction healing, and periodontal therapy.
This is a significant undertaking because the evidence for HBOT in dentistry is scattered across dozens of small studies, different protocols, and different patient populations. Nobody had pulled it all together quite like this before.
📊 What the evidence shows
Osteoradionecrosis: promising early, disappointing late
This is where the most research exists — and where the picture is most complicated.
For early-stage ORN (where there's bone damage but no fractures or major tissue death), the signals are encouraging. A cohort study from Thailand with 84 patients observed enhanced healing when HBOT was used alongside surgery for stage I-II disease. Meta-analyses found that the combination of HBOT plus surgery achieved higher rates of lesion resolution than either treatment alone.
But for advanced ORN — with pathological fractures and full-thickness bone death — HBOT doesn't appear to change much. The biology makes sense: once bone is so damaged that the blood supply is effectively gone, pumping in extra oxygen may not be enough to restart regeneration. At that point, surgical resection is typically the only option.
The biggest blow came from the HOPON trial — the most rigorous study to date. Among 144 patients, ORN rates were virtually identical between HBOT (6.4%) and control (5.7%) groups. No benefit detected. The reviewers note, though, that modern radiotherapy techniques have lowered ORN rates so much that any study would need enormous sample sizes to detect a modest benefit.
Jaw necrosis from medications (MRONJ): one real trial, intriguing results
There's only one randomized controlled trial on HBOT for MRONJ — and its findings are genuinely interesting. Freiberger et al. enrolled 49 patients with bisphosphonate-related jaw necrosis. Clinical improvement was observed in 68% of HBOT-treated patients versus 38% of controls. Pain resolved faster. Time to improvement was nearly halved (39.7 vs 67.9 weeks).
But — complete mucosal healing wasn't significantly different between groups. So HBOT appeared to help patients feel better and recover faster, without necessarily achieving full bone regeneration. That's a meaningful distinction: it suggests HBOT may be excellent at improving the healing environment and reducing symptoms, while not being a cure for the underlying bone damage.
An earlier case series found that patients who continued taking bisphosphonates during HBOT had significantly earlier disease recurrence — suggesting that drug holiday timing matters.
Dental implants in irradiated patients: no survival advantage
This is where the evidence is most clearly negative. Multiple meta-analyses — covering thousands of implants — found that HBOT did not improve implant survival in irradiated jaws. The only RCT (26 patients) found no differences in implant failure, complications, or patient satisfaction.
The explanation isn't that HBOT does nothing biologically. Animal studies consistently show that HBOT enhances early healing markers — more blood vessel growth, better bone-to-implant contact, more mineralization. But these early-phase gains don't appear to translate into long-term implant survival in human patients with radiation-damaged bone.
Post-extraction healing and periodontal therapy: early signals, limited data
Animal studies show that HBOT significantly improves bone preservation and healing after tooth extraction — better ridge maintenance, higher bone density, more growth factor expression. In diabetic animal models, HBOT improved early bone-to-implant contact, though the benefit faded by 8 weeks.
Human evidence in periodontal therapy is sparse and inconclusive. Small studies suggest short-term benefits, but nothing large or rigorous enough to draw conclusions from.
⚖️ Where the evidence is strong — and where it isn't
Let's be direct about what this 25-year evidence pile actually tells us:
Where HBOT looks most promising: Early-stage ORN and MRONJ, where tissues are oxygen-starved and inflamed but not yet irreversibly destroyed. The one MRONJ trial showed meaningful symptom improvement. Multiple observational studies support HBOT as an adjunct to surgery in early jaw necrosis.
Where it clearly doesn't work: Improving dental implant survival in irradiated patients. The data here is about as close to settled as it gets in this field — multiple meta-analyses, one RCT, consistent null results.
Where we simply don't know yet: Advanced-stage ORN, periodontal regeneration, post-extraction healing in humans, and optimal protocols for any of these. The biggest barrier isn't that the biology doesn't make sense — it does. It's that nearly every study uses different pressures (2.0-2.8 ATA), different session counts (10-60), different timing, and measures different outcomes. Until there's agreement on what to test, the evidence will stay fragmented.
The honest bottom line from the reviewers themselves: HBOT may be considered in selected clinical scenarios where healing is impaired by hypoxia or systemic disease. But current evidence is insufficient to support routine use for any dental indication.
📌 Takeaway for the community
- A comprehensive review of 123 studies spanning 25 years found that HBOT shows the most promise in early-stage jaw necrosis (both radiation- and medication-related), where it was associated with improved healing and symptom relief when used alongside surgery
- The only RCT for medication-related jaw necrosis observed clinical improvement in 68% of HBOT patients vs 38% of controls, with faster pain resolution — but complete bone healing was not significantly different
- For dental implants in irradiated patients, multiple meta-analyses found no survival advantage from HBOT — despite positive signals in animal studies
- The biggest obstacle across all dental HBOT research is massive variation in protocols, making it nearly impossible to compare studies or establish which approach works best
- All studies reviewed used clinical-grade HBOT at 2.0-2.8 ATA with 100% medical oxygen — not comparable to consumer wellness chambers
Source: https://www.mdpi.com/2077-0383/15/2/605
Wiśniewska B, Piekarski K, Spychała S, Golusińska-Kardach E, Perek B, Wyganowska ML. HBOT as a Potential Adjunctive Therapy for Wound Healing in Dental Surgery — A Narrative Review. J Clin Med. 2026;15(2):605. doi: 10.3390/jcm15020605.
Educational disclaimer
This content summarizes findings from published medical research for educational purposes only.
The hyperbaric chambers sold on this website are non-medical wellness devices and are not intended to diagnose, treat, cure, or prevent any disease.
The studies discussed here were conducted in clinical medical settings using medical-grade interventions. The inclusion of research summaries does not imply that similar outcomes can be achieved using non-medical wellness devices.
